CRIS Current Research Information System

GALIE', NAZZARENO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.958
AS - Asia 17.900
EU - Europa 12.393
SA - Sud America 1.346
Continente sconosciuto - Info sul continente non disponibili 959
AF - Africa 954
OC - Oceania 27
Totale 53.537
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.552
SG - Singapore 4.808
VN - Vietnam 4.648
CN - Cina 4.360
GB - Regno Unito 2.883
IT - Italia 2.664
DE - Germania 1.595
HK - Hong Kong 1.323
BR - Brasile 963
FR - Francia 915
SE - Svezia 813
IN - India 800
UA - Ucraina 705
RU - Federazione Russa 700
IE - Irlanda 497
NL - Olanda 422
BD - Bangladesh 335
KR - Corea 335
JP - Giappone 320
FI - Finlandia 286
ZA - Sudafrica 282
CI - Costa d'Avorio 255
CA - Canada 211
EE - Estonia 199
AR - Argentina 156
CH - Svizzera 150
TG - Togo 134
JO - Giordania 131
PH - Filippine 111
ID - Indonesia 109
AT - Austria 107
SC - Seychelles 98
BG - Bulgaria 92
TH - Thailandia 92
TR - Turchia 90
IQ - Iraq 85
MX - Messico 74
PL - Polonia 66
PK - Pakistan 65
EC - Ecuador 60
CO - Colombia 53
TW - Taiwan 52
ES - Italia 48
BE - Belgio 44
SA - Arabia Saudita 41
NG - Nigeria 39
CL - Cile 35
GR - Grecia 32
JM - Giamaica 32
EG - Egitto 30
UZ - Uzbekistan 30
IR - Iran 28
AU - Australia 23
VE - Venezuela 23
HU - Ungheria 22
LT - Lituania 22
PY - Paraguay 21
CR - Costa Rica 20
MY - Malesia 20
RO - Romania 20
PE - Perù 19
HR - Croazia 18
MA - Marocco 17
KE - Kenya 16
DZ - Algeria 15
HN - Honduras 15
LB - Libano 15
AL - Albania 14
CZ - Repubblica Ceca 14
AZ - Azerbaigian 13
GT - Guatemala 13
NE - Niger 13
UY - Uruguay 13
AE - Emirati Arabi Uniti 12
KZ - Kazakistan 12
ET - Etiopia 11
DK - Danimarca 10
DO - Repubblica Dominicana 10
NI - Nicaragua 10
OM - Oman 10
PS - Palestinian Territory 9
TN - Tunisia 9
XK - ???statistics.table.value.countryCode.XK??? 9
SK - Slovacchia (Repubblica Slovacca) 8
SY - Repubblica araba siriana 8
IL - Israele 7
PT - Portogallo 7
RS - Serbia 7
SN - Senegal 6
GH - Ghana 5
NP - Nepal 5
SV - El Salvador 5
A2 - ???statistics.table.value.countryCode.A2??? 4
EU - Europa 4
GE - Georgia 4
LU - Lussemburgo 4
LV - Lettonia 4
MK - Macedonia 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
Totale 52.513
Salva come PNG Salva come JPEG
Città #
Singapore 3.325
Southend 2.439
Ashburn 1.970
Fairfield 1.759
Hong Kong 1.265
San Jose 1.212
Ho Chi Minh City 1.079
Chandler 1.061
Hanoi 940
Woodbridge 883
Wilmington 807
Seattle 747
Houston 746
Hefei 715
Santa Clara 697
Beijing 680
Dong Ket 674
Princeton 648
Cambridge 594
Council Bluffs 575
Dublin 492
Boardman 466
Jacksonville 440
Ann Arbor 421
Lauterbourg 391
Bologna 362
Los Angeles 311
Seoul 279
New York 276
Tokyo 276
Westminster 260
Abidjan 255
Padova 248
Milan 242
Nanjing 241
Berlin 193
Buffalo 189
Helsinki 171
São Paulo 150
The Dalles 150
Jinan 148
Turin 146
Haiphong 144
Dallas 143
Da Nang 135
Lomé 133
Saint Petersburg 127
Amman 126
San Diego 126
Shenyang 123
Redondo Beach 120
Rome 120
Frankfurt am Main 112
Bern 110
Guangzhou 101
Mülheim 94
Changsha 91
Sofia 89
Hebei 84
Bengaluru 82
Shanghai 81
Chicago 80
Medford 79
Munich 78
London 73
Tianjin 73
Nuremberg 72
Phoenix 72
Des Moines 70
Nanchang 65
Lappeenranta 62
Hangzhou 61
Vienna 61
Jiaxing 58
Zhengzhou 58
Johannesburg 54
Turku 52
Toronto 50
Warsaw 50
Florence 48
Mahé 48
Redmond 48
Biên Hòa 47
Jakarta 47
Can Tho 46
Yubileyny 45
Dearborn 44
Enfield 44
Shenzhen 44
Olalla 43
Amsterdam 42
Atlanta 42
Bangkok 42
Brussels 42
Hải Dương 42
Falls Church 41
Bremen 40
San Francisco 40
Orem 39
Thái Nguyên 39
Totale 33.145
Salva come PNG Salva come JPEG
Nome #
Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA 447
Prolasso valvolare mitralico e disgiunzione mitro-anulare. La consapevolezza di un possibile substrato aritmico 387
[Pulmonary hypertension in chronic lung diseases] 295
Sex-Related Disparities in Cardiac Masses: Clinical Features and Outcomes 288
Female gender and mortality in ST-segment-elevation myocardial infarction treated with primary PCI 286
Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells 274
Is Pulmonary Artery Pulsatility Index (PAPi) a Predictor of Outcome after Pulmonary Endarterectomy? 271
L’angioplastica delle arterie polmonari nel cuore polmonare cronico tromboembolico: 5 anni di esperienza in Italia 268
A new CT-score as index of hemodynamic changes in patients with chronic thromboembolic pulmonary hypertension 261
Complicanze del cateterismo cardiaco destro in pazienti con ipertensione polmonare precapillare di grado severo. 259
Lung neovascularity in pulmonary arterial hypertension associated with congenital heart defects and idiopathic pulmonary arterial hypertension: study of 198 patients 256
A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension 254
2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. 250
Diagnostic Accuracy of Cardiac Computed Tomography and 18F-Fluorodeoxyglucose With Positron Emission Tomography in Cardiac Masses 249
Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: Real-world insights 247
Angioplastica delle arterie polmonari nel cuore polmonare cronico tromboembolico: un caso clinico paradigmatico 238
Il test acuto di vasoreattività nei pazienti con ipertensione arteriosa polmonare. 236
Evaluation of mosaic pattern areas in HRCT with Min-IP reconstructions in patients with pulmonary hypertension: could this evaluation replace lung perfusion scintigraphy? 231
Electrocardiogram analysis in Anderson-Fabry disease: a valuable tool for progressive phenotypic expression tracking 229
Pulmonary Arterial Hypertension associated to connective tissue diseases 229
Effetti emodinamici e funzionali dell'epoprostenolo in associazione agli antagonisti recettoriali dell'endotelina e agli inibitori delle fosfodiesterasi-5 227
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 224
Application of a new pulmonary artery obstruction score in the prognostic evaluation of acute pulmonary embolism: comparison with clinical and haemodynamic parameters [Applicazione di un nuovo score di ostruzione vascolare nella valutazione prognostica dell'embolia polmonare acuta. Confronto con i parametri clinico-emodinamici] 220
Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes 217
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension 215
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people 208
Regressione delle alterazioni elettrocardiografiche indicative di ipertrofia ventricolare destra nei pazienti con ipertensione arteriosa polmonare. 207
In vitro thrombogenicity of drug-eluting and bare metal stents 207
Aiming at the appropriate target for the treatment of pulmonary hypertension due to left heart disease 205
Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study 204
Secondary prevention medical therapy and outcomes in patients with myocardial infarction with non-obstructive coronary artery disease 200
BMPR2 mutations and survival in pulmonary arterial hypertension: An individual participant data meta-analysis 199
Use of Diltiazem in Chronic Rate Control for Atrial Fibrillation: A Prospective Case-Control Study 198
Genetics and clinical phenotype of Erdheim–Chester disease: A case report of constrictive pericarditis and a systematic review of the literature 197
Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration 197
Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. 196
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension 194
[Pulmonary hypertension due to left heart diseases] 194
Development and Validation of a Diagnostic Echocardiographic Mass Score in the Approach to Cardiac Masses 193
Andamento clinico, emodinamico e dei livelli plasmatici dell’NT-pro BNP in pazienti con ipertensione polmonare precapillare 193
Occurring of In Vitro Functional Vasculogenic Pericytes from Human Circulating Early Endothelial Precursor Cell Culture 192
Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. 192
Correlations Between Cardiac Magnetic Resonance and Myocardial Histologic Findings in Fabry Disease 189
Densitometric CT evaluation of acute and chronic thromboembolic filling defects of the pulmonary arteries before and after contrast injection = Valutazione densitometrica dei difetti di riempimento tromboembolici acuti e cronici delle arterie polmonari prima e dopo somministrazione di mezzo di contrasto 189
Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson–Fabry disease 189
Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team 188
Ambrisentan therapy for pulmonary arterial hypertension. 186
A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines 186
Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition. 185
Clinical presentations leading to arrhythmogenic left ventricular cardiomyopathy 182
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. 182
Effetti del trattamento con sildenafil nei pazienti con ipertensione arteriosa polmonare idiopatica, associata e cuore polmonare cronico tromboembolico. 182
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension 182
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. 181
Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA 181
Genere femminile e ipertensione arteriosa polmonare: una relazione complessa Female gender and pulmonary arterial hypertension: a complex relationship 180
Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. 179
Anticoagulant treatment in patients with pulmonary arterial hypertension associated with systemic sclerosis: More shadows than lights 179
Significato prognostico dell'aerea del rigurgito tricuspidalico nei pazienti con ipertensione arteriosa polmonare idiopatica trattati secondo le attuali linee guida. 178
Preoperative checklist to reduce the risk of cardiac implantable electronic device infections 177
The endothelin system in pulmonary arterial hypertension. 176
Effetti clinici ed emodinamici del trattamento con sildenafil nei pazienti con ipertensione arteriosa polmonare. 176
Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. 176
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS 176
New insights on pulmonary arterial hypertension. 175
Pulmonary endarterectomy: is there an alternative to profound hypothermia with cardiocirculatory arrest? 175
Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. 175
Current therapeutic approaches to pulmonary arterial hypertension. 175
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. 172
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism 172
Sildenafil therapy in patients with porto-pulmonary hypertension 171
Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study 171
Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients 170
Pulmonary Arterial Hypertension Associated with Portal Hypertension and HIV Infection: Comparative Characteristics and Prognostic Predictors 169
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. 169
Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension 168
Clinical classification of pulmonary hypertension. 167
Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina 167
Primary malignant pericardial tumour in Lynch syndrome 166
Cardiologia pediatrica. Problematiche cliniche 165
Pulmonary endarterectomy: an alternative to circulatory arrest and deep hypothermia: mid-term results 164
Confronto tra antagonista recettoriali selettivi e non selettivi dell'endotelina nel trattamento dell'ipertensione arteriosa polmonare. 164
Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study 163
The role of physical activity in individuals with cardiovascular risk factors: An opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport 163
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients 163
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. 162
Predicting and improving outcomes of transcatheter aortic valve replacement in older adults and the elderly 162
Pulmonary hypertension in primary Sjogren's syndrome: report of a case and review of the literature. 161
Pulmonary arterial hypertension. Part II: Medical and surgical treatment 161
Coronary Protection to Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement: A Multicenter International Registry 161
Prognostic value of high-sensitivity cardiac troponin I early after coronary artery bypass graft surgery 160
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS) 160
Impact of Elective, Uncomplicated Target Lesion Revascularization on Cardiac Mortality After Elective Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease 160
Effetti del sildenafil in soggetti con cuore polmonare cronico tromboembolico 159
Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. 158
Rare causes of pulmonary hypertension. Spectrum of radiological findings and review of the literature 158
European guidelines on pulmonary hypertension: What's new? 158
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study 156
Pulmonary veno-occlusive disease: the role of CT 156
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension 156
Totale 19.865
Salva come PNG Salva come JPEG
Categoria #
all - tutte 160.481
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 160.481
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.531 0 180 333 320 431 271 125 419 186 267 1.082 917
2022/20235.527 548 694 263 660 294 398 205 275 1.006 235 563 386
2023/20241.793 134 258 107 148 161 264 103 134 79 190 95 120
2024/20257.519 323 1.261 794 504 1.037 469 492 248 173 475 382 1.361
2025/202618.826 1.492 1.746 1.729 1.447 2.090 1.003 1.941 687 3.767 1.329 821 774
2026/20271.682 787 895 0 0 0 0 0 0 0 0 0 0
Totale 53.537